|

ONO-4685 Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1: 2

Top Sponsors

  • Ono Pharmaceutical Co. Ltd2

Indications

  • Cancer2
  • Relapsed or Refractory T Cell Lymphoma1
  • Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma1

Other1 trial

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
Phase 1

Birmingham, Alabama1 trial

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

University of Alabama at Birmingham

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.